Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| NSI-189 | Piracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 40 mg once daily (for educational context — investigational compound, not approved for any indication) | 1200-4800 mg/day divided into 2-3 doses |
| Timing | Once daily, time of day not definitively established from clinical data. With or without food. | With or without food; split doses morning and afternoon to maintain plasma levels |
| Cycle Duration | Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable. | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment |
| Evidence Level | moderate_human | moderate_human |
Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.
40 mg once daily (for educational context — investigational compound, not approved for any indication)
Once daily, time of day not definitively established from clinical data. With or without food.
Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.
Positive allosteric modulator of AMPA receptors, binding at a unique site along the dimer interface to reduce desensitization and deactivation. Inhibits N-type calcium channels at clinically relevant CNS concentrations. Enhances membrane fluidity of neuronal phospholipids and modulates neurotransmission across cholinergic and glutamatergic systems.
1200-4800 mg/day divided into 2-3 doses
With or without food; split doses morning and afternoon to maintain plasma levels
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →